TNF Inhibitors Do Not Increase Risk of Tumor Malignancy in Pediatric IBD, Study Shows

TNF Inhibitors Do Not Increase Risk of Tumor Malignancy in Pediatric IBD, Study Shows
Treatment of pediatric inflammatory bowel disease (pIBD) with tumor necrosis factor inhibitors (TNFi) does not increase the risk for malignancy, researchers report. The study with that finding, “Risk of malignancy associated with paediatric use of tumour necrosis factor inhibitors,” was published in the journal Annals of the Rheumatic Disease. TNF is a pro-inflammatory cytokine, which is a

Knowledge is power when living with IBD.

Get access to the web’s leading IBD news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *